To be in forefront of the AMR crisis, it is necessary that Nordic research environments within AMR collaborate across disciplines and sectors. It is also important for the Nordic countries that the AMR research efforts are aligned, and coordinated to avoid overlapping and research waste, and instead are set to harvest synergies from Nordic research to tackle the creeping crisis, states NordForsk.  

Related article

New Danish alliance with the goal to combat AMR

Pfizer Denmark, Pharmadanmark and the Novo Nordisk Foundation have initiated the alliance and aim to prevent the growing spread of antimicrobial resistance (AMR). “The challenge of antimicrobial resistance cannot be solved by one country alone and requires a global effort. Denmark can play an important role in this by establishing significant initiatives that can inspire […]

As part of the combat against AMR, the European Commission plans to invest up to EUR 100 million in the seven-year long co-funded European Partnership: One Health Anti-Microbial Resistance (OHAMR). The OHAMR-partnership will be implemented through joint transnational calls for proposals and additional activities from 2025 and onwards. In addition, the European partnership on Animal Health and Welfare (EUPAHW) is designed to i.e. prevent and control infectious animal diseases and promote prudent use of antimicrobials. Both partnerships and other relevant calls from the EU framework program are attractive arenas for funding of collaborative, cutting edge research.

The overall aim of the call is to contribute to the Nordic Council of Ministers’ focus area fighting AMR, and to do so by strengthening the Nordic AMR research environments, and secure long-term recruitment to this area of research while supporting alignment and synergies of research efforts.

The overall aim of the call is to contribute to the Nordic Council of Ministers’ focus area fighting AMR, and to do so by strengthening the Nordic AMR research environments, and secure long-term recruitment to this area of research while supporting alignment and synergies of research efforts, stated NordForsk. More specific aims are to provide young researchers with experience in leading international projects within One Health AMR, and to increase the attraction of research funding from EU programs and initiatives to Nordic research environments.  

The leaders of the networks are younger researchers, with two to seven years’ experience since completing their PhD, who will gain valuable experience from international project organization and management.

The work they will lead is about working together with their Nordic partners to develop and participate in applications to EU calls for AMR.

A total of NOK 4.8 million was granted, and each network will receive NOK 800,000. 

The network call was funded by the Nordic Council of Ministers and NordForsk. A total of NOK 4.8 million was granted, and each network will receive NOK 800,000. 

The projects have a duration of two years, and start as early as December 2024. In order to monitor the long-term effect of the award, the project owners have undertaken to deliver reports on the results of the network funds for up to five years after the funding period has ended.

Related article

#WAAW: Interview – AdjuTec Pharma

Norwegian company AdjuTec’s novel antibiotic resistance breakers may help to facilitate reduced use of antibiotics – and the company is now ready to test its product in humans.

Funded projects

World AMR Awareness Week

A global action plan to tackle the growing problem of resistance to antibiotics and other antimicrobial medicines was endorsed at the 68th World Health Assembly in May 2015. One of the key objectives of the plan is to improve awareness and understanding of AMR through effective communication, education and training. The World AMR Awareness Week takes place 18th to 24th November 2024.

Antimicrobial resistance

Antimicrobial resistance (AMR) occurs when bacteria, viruses, fungi and parasites change over time and no longer respond to medicines, making infections harder to treat and increasing the risk of disease spread, severe illness and death. As a result of drug resistance, antibiotics and other antimicrobial medicines become ineffective and infections become increasingly difficult or impossible to treat.